Abstract
Background: Nitric oxide (NO) is constitutively produced in the lung by NO-synthases. The main cellular sources of lung NO production are the vascular endothelium and the airway epithelia (Bohle et al. 2000; German et al. 2000; Ide et al. 1999). Local NO production contributes to regulation of pulmonary perfusion depending on alveolar ventilation to assure optimized ventilation/perfusion distribution (Grimminger et al. 1995). NO-synthase activity is regulated on transcriptional and post-translational redox-based modulation level. The common signaling pathway of endogenous vasodilators, such as nitric oxide, prostaglandins, and natriuretic peptides, engage cyclic nucleotides (cAMP and cGMP). These second messengers are mainly produced by activation of adenylate- and guanylate-cyclases, both membrane-bound and soluble (Beavo 1995). Phosphodiesterases (PDEs) represent a superfamily of enzymes, with PDE1 through PDE11 being currently known, that inactivate cyclic AMP and cyclic GMP, with different tissue distribution and substrate specificities (Ahn et al. 1991; Von Euler and Liljestrand. 1946). Because of stabilization of these second messengers, PDE inhibitors differentially regulate levels of cAMP and/or cGMP, depending on their selectivity profile. Recently, direct activators and stimulators of the sGC have been suggested as new therapeutic tools for the treatment of lung vascular disorders that might have even higher potency than PDE inhibitors or exogenously applied NO.
Chapter PDF
References
Abrams D, Schulze-Neick I, Magee AG (2000) Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84:E4
Agusti AG, Rodriguez-Roisin R (1993) Effect of pulmonary hypertension on gas exchange. Eur Respir J 6:1371–1377
Ahn HS, Foster M, Cable M, Pitts BJ, Sybertz EJ (1991) Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol 308:191–197
Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple iso-forms. Physiol Rev 75:725–748
Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, Burnett JC Jr (2003) Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41–2272 in experimental congestive heart failure. Circulation 107: 686–689
Bohle RM, Hartmann E, Kinfe T, Ermert L, Seeger W, Fink L (2000) Cell type-specific mRNA quantitation in non-neoplastic tissues after laser-assisted cell picking. Pathobiology 68: 191–195
Carlsen J, Kjeldsen K, Gerstoft J (2002) Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 16:1568–1569
Channick RN, Newhart JW, Johnson FW, Williams PJ, Auger WR, Fedullo PF, Moser KM (1996) Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 109:1545–1549
Cohen AH, Hanson K, Morris K, Fouty B, McMurty IF, Clarke W, Rodman DM (1996) Inhibition of cyclic 3′–5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest 97:172–179
Corbin JD, Francis SH (2002) Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56:453–459
Egan JJ (1999) New treatments for pulmonary fibrosis? Lancet 354:1839–1840
Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, Bloch KD, Zapol WM (2004) Soluble guanylate cyclase activator reverses acute pulmonary hypertension and aug ments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110:2253–2259
Francis SH, Chu DM, Thomas MK, Beasley A, Grimes K, Busch JL, Turko IV, Haik TL, Corbin JD (1998) Ligand-induced conformational changes in cyclic nucleotide phosphodiesterases and cyclic nucleotide-dependent protein kinases. Methods 14:81–92
Friebe A, Koesling D (1998) Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol 53:123–127
Friebe A, Schultz G, Koesling D (1996) Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J 15:6863–6868
Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz G, Koesling D (1998) YC-1 poten tiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol 54:962–967
Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G (2005) Sildenafil citrate therapy for pul monary arterial hypertension. N Engl J Med 353:2148–2157
Galle J, Zabel U, Hubner U, Hatzelmann A, Wagner B, Wanner C, Schmidt HH (1999) Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phos phodiesterase activity. Br J Pharmacol 127:195–203
German Z, Chambliss KL, Pace MC, Arnet UA, Lowenstein CJ, Shaul PW (2000) Molecular basis of cell-specific endothelial nitric-oxide synthase expression in airway epithelium. J Biol Chem 275:8183–8189
Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F (2002a) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136:515–522
Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F (2002b) Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360:895–900
Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F (2003a) Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42: 158–164
Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A, Olschewski H, Weissmann N, Enke B, Ghofrani S, Seeger W, Grimminger F (2003b) Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 167:1139–1141
Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B, Schermuly RT, Weissmann N, Seeger W, Grimminger F (2004) Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 44: 1488–1496
Gopal VK, Francis SH, Corbin JD (2001) Allosteric sites of phosphodiesterase-5 (PDE5). A po tential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem 268:3304–3312
Grimminger F, Spriestersbach R, Weissmann N, Walmrath D, Seeger W (1995) Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs. J Appl Physiol 78: 1509–1515
Hassoun PM, Filippov G, Fogel M, Donaldson C, Kayyali US, Shimoda LA, Bloch KD (2004) Hypoxia decreases expression of soluble guanylate cyclase in cultured rat pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 30:908–913
Higenbottam T, Siddons T, Demoncheaux E (2000) A therapeutic role for chronic inhaled nitric oxide? Lancet 356:446–447
Hillier SC, Graham JA, Hanger CC, Godbey PS, Glenny RW, Wagner WW Jr (1997) Hypoxic vasoconstriction in pulmonary arterioles and venules. J Appl Physiol 82:1084–1090
Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H (2000) Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 342:1866–1870
Huai Q, Liu Y, Francis SH, Corbin JD, Ke H (2004) Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determi nant of inhibitor selectivity. J Biol Chem 279:13095–13101
Ide H, Nakano H, Ogasa T, Osanai S, Kikuchi K, Iwamoto J (1999) Regulation of pulmonary circulation by alveolar oxygen tension via airway nitric oxide. J Appl Physiol 87:1629–1636
Kothari SS, Duggal B (2002) Chronic oral sildenafil therapy in severe pulmonary artery hyperten sion. Indian Heart J 54:404–409
Lepore JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM, Bloch KD, Semigran MJ (2002) Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 90:677–680
Li D, Zhou N, Johns RA (1999) Soluble guanylate cyclase gene expression and localization in rat lung after exposure to hypoxia. Am J Physiol 277:L841–L847
Li D, Laubach VE, Johns RA (2001) Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS. Am J Physiol Lung Cell Mol Physiol 281: L369–L376
Melot C, Lejeune P, Leeman M, Moraine JJ, Naeije R (1989) Prostaglandin E1 in the adult res piratory distress syndrome. Benefit for pulmonary hypertension and cost for pulmonary gas exchange. Am Rev Respir Dis 139:106–110
Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S (2002) Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105:2398–2403
Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL (2003) Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108:2066–2069
Moncada I, Jara J, Subira D, Castano I, Hernandez C (2004) Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol 46:357–360
Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, Koesling D (2003) Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol 160:719–727
Mulsch A, Bauersachs J, Schafer A, Stasch JP, Kast R, Busse R (1997) Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol 120:681–689
Oliver J, Webb DJ (2002) Sildenafil for “blue babies”. Such unlicensed drug use might be justified as last resort. BMJ 325:1174
Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W (1996) Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124:820–824
Olschewski H, Ghofrani HA, Walmrath D, Temmesfeld-Wollbruck B, Grimminger F, Seeger W (1998) Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med 24:631–634
Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, Seeger W (1999) Inhaled prostacyclin and iloprost in severe pulmonary hy pertension secondary to lung fibrosis. Am J Respir Crit Care Med 160:600–607
Olschewski H, Ghofrani HA, Schmehl T, Winkler J, Wilkens H, Hoper MM, Behr J, Kleber FX, Seeger W (2000) Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 132:435–443
Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W (2002) Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347:322–329
Patole S, Travadi J (2002) Sildenafil for “blue babies”. Ethics, conscience, and science have to be balanced against limited resources. BMJ 325:1174
Prasad S, Wilkinson J, Gatzoulis MA (2000) Sildenafil in primary pulmonary hypertension. N Engl J Med 343:1342
Radermacher P, Santak B, Becker H, Falke KJ (1989) Prostaglandin E1 and nitroglycerin reduce pulmonary capillary pressure but worsen ventilation-perfusion distributions in patients with adult respiratory distress syndrome. Anesthesiology 70:601–606
Reichenberger F, Voswinckel R, Enke B, Rutsch M, Fechtali EE, Schmehl T, Olschewski H, Schermuly R, Weissmann N, Ghofrani HA, Grimminger F, Mayer E, Seeger W (2007) Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 30:922–927
Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM (1993) Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 328:399–405
Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336:111–117
Sastry BK, Narasimhan C, Reddy NK, Anand B, Prakash GS, Raju PR, Kumar DN (2002) A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J 54:410–414
Sastry BK, Narasimhan C, Reddy NK, Raju BS (2004) Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43:1149–1153
Schermuly RT, Roehl A, Weissmann N, Ghofrani HA, Schudt C, Tenor H, Grimminger F, Seeger W, Walmrath D (2000) Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with im provement in gas exchange. J Pharmacol Exp Ther 292:512–520
Schumacher YO, Zdebik A, Huonker M, Kreisel W (2001) Sildenafil in HIV-related pulmonary hypertension. AIDS 15:1747–1748
Singh B, Gupta R, Punj V, Ghose T, Sapra R, Grover DN, Kaul U (2002) Sildenafil in the manage ment of primary pulmonary hypertension. Indian Heart J 54:297–300
Stasch JP, Becker EM, onso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schroder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M (2001) NO-independent regulatory site on soluble guanylate cyclase. Nature 410:212–215
Stasch JP, Schmidt P, onso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, Wunder F (2002) NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136:773–783
Straub A, Stasch JP, onso-Alija C, et-Buchholz J, Ducke B, Feurer A, Furstner C (2001) NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett 11:781–784
Teng CM, Wu CC, Ko FN, Lee FY, Kuo SC (1997) YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 320: 161–166
Von Euler US, Liljestrand G (1946) Observations on the pulmonary arterial blood pressure in the cat. Acta Physiol Scand 12:301–320
Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger W (1993) Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 342:961–962
Watanabe H, Ohashi K, Takeuchi K, Yamashita K, Yokoyama T, Tran QK, Satoh H, Terada H, Ohashi H, Hayashi H (2002) Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 71:398–402
Wegener JW, Nawrath H (1997) Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle. Eur J Pharmacol 323:89–91
Weissmann N, Voswinckel R, Tadic A, Hardebusch T, Ghofrani HA, Schermuly RT, Seeger W, Grimminger F (2000) Nitric oxide (NO)-dependent but not NO-independent guanylate cy-clase activation attenuates hypoxic vasoconstriction in rabbit lungs. Am J Respir Cell Mol Biol 23:222–227
Weissmann N, Grimminger F, Olschewski A, Seeger W (2001) Hypoxic pulmonary vasoconstric-tion: a multifactorial response? Am J Physiol Lung Cell Mol Physiol 281:L314–L317
Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW (2001) Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104:1218–1222
Wu CC, Ko FN, Kuo SC, Lee FY, Teng CM (1995) YC-1 inhibited human platelet aggrega tion through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 116: 1973–1978
Zhao L, Mason NA, Strange JW, Walker H, Wilkins MR (2003) Beneficial effects of phosphodi-esterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. Circulation 107:234–237
Zimmermann AT, Calvert AF, Veitch EM (2002) Sildenafil improves right-ventricular parameters and quality of life in primary pulmonary hypertension. Intern Med J 32:424–426
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer
About this chapter
Cite this chapter
Ghofrani, HA., Grimminger, F. (2009). Modulating cGMP to Treat Lung Diseases. In: Schmidt, H.H.H.W., Hofmann, F., Stasch, JP. (eds) cGMP: Generators, Effectors and Therapeutic Implications. Handbook of Experimental Pharmacology, vol 191. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68964-5_20
Download citation
DOI: https://doi.org/10.1007/978-3-540-68964-5_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-68960-7
Online ISBN: 978-3-540-68964-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)